EVOLUTION Life Science Partners

What EVOLUTION Life Science Partners does

EVOLUTION Life Science Partners is a boutique investment bank founded in 2014 that provides licensing, strategic advisory, M&A, and capital raising services exclusively to life sciences and healthcare companies. The firm is headquartered in San Francisco with bankers distributed across New York, San Francisco, and Philadelphia, and is co-led by Senior Managing Director Mary Tanner and Managing Director Anton Gueth, following the 2021 passing of founding Chairman Frederick Frank. The senior team averages 25 years of investment banking and industry experience, with prior tenures at Lehman Brothers, Bear Stearns, Eli Lilly, GlaxoSmithKline, Bain & Company, and Burrill Securities, and cites aggregate lifetime deal value in excess of $125 billion.

The firm delivers four integrated service modules: Licensing (including cross-border deals with China-based companies), M&A Advisory (covering transactions regardless of size), Capital Raising (Series B, PIPEs, Registered Directs, with relationships across VCs, Crossover Funds, and specialty investors), and Strategic Advisory (including cGMP manufacturing supply problem-solving and non-dilutive product development strategies). Securities products and broker-dealer services are delivered through a separate, unaffiliated registered broker-dealer, BA Securities, LLC (member FINRA/SIPC). The firm has no proprietary technology platform and no disclosed AI/ML capabilities.

EVOLUTION generates revenue exclusively through transaction-based advisory fees negotiated on a per-engagement basis, with engagements described as multi-year contractual arrangements. Customer segments are segmented by vertical — primarily large pharma and biotechnology, with secondary coverage of medical device and molecular diagnostic companies. The go-to-market is enterprise field sales through direct advisory relationships maintained by senior bankers, and the firm deliberately selects clients by interest level rather than deal fee size.

Name

EVOLUTION Life Science Partners

Legal name

EVOLUTION Life Science Partners

Website

https://evolutionlsp.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

EVOLUTION Life Science Partners is a boutique investment bank providing licensing, M&A, capital raising, and strategic advisory services to large pharma, biotechnology, medical device, and molecular diagnostic companies across their lifecycle.

Ownership category

akta.pro rank

Product category

Life Sciences Investment Banking

NAICS

Management, Scientific, and Technical Consulting Services (5416)

SIC

Security Brokers, Dealers & Flotation Companies (6211), Investment Advice (6282)

akta.pro primary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

Keywords

• Life sciences investment banking
• M&A advisory services
• Biotech capital raising
• Pharmaceutical licensing
• Healthcare strategic advisory

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Investment Banking Advisory Fees: The firm generates revenue through advisory fees for licensing, strategic advisory, M&A transactions, and capital raising services. Securities Products and Investment Banking Services are offered through BA Securities, LLC, member FINRA and SIPC.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

EVOLUTION Life Science Partners is a boutique investment bank that advises life sciences and healthcare companies on licensing transactions, strategic advisory engagements, mergers and acquisitions, and capital raising activities. The firm serves large global pharmaceutical players, biotech start-ups, medical device companies, and molecular diagnostics firms, including overseas companies in China, with engagements ranging from corporate partnering and minority investments to Series B rounds, PIPEs, and Registered Directs.

Product overview

EVOLUTION Life Science Partners operates as a unified investment banking platform offering four integrated service modules: Licensing, M&A Advisory, Capital Raising, and Strategic Advisory. These services work together to assist life science and healthcare companies throughout their lifecycle—from capital raising and licensing/partnering to M&A transactions. The firm covers large pharma, biotechnology, medical device, and molecular diagnostic sectors. Securities Products and Investment Banking Services are offered through BA Securities, LLC.

Differentiator

Problem solved

Functional benefit

Products and services

• Licensing Services Licensing advisory services for life sciences companies, covering transactions for large global pharmaceutical players, small biotech start-ups, and overseas companies in China seeking partnerships and deal-making opportunities.
• M&A Advisory M&A advisory services for life sciences transactions across multiple deal sizes, with the firm selecting clients based on interest level and desire for challenge rather than deal fees.
• Capital Raising Capital raising services covering Series B rounds, PIPEs, and Registered Directs, leveraging relationships with venture capital firms, crossover funds, and specialty investors for life sciences clients.
• Strategic Advisory Strategic advisory services addressing operational challenges in life sciences, including solving cGMP manufacturing supply problems and creating unique strategies to advance product development without dilution.

Quantifiable outcome

• Senior bankers have executed hundreds of M&A, partnering, and capital raising engagements with aggregate deal value in excess of $125 billion
• +1 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Lazard: Global advisory and asset management firm with a long-standing healthcare M&A practice; competes for larger pharma and biotech M&A mandates and represents a broader incumbent player in life sciences advisory.
• Guggenheim Securities: Diversified investment bank with a healthcare practice spanning M&A, equity, and debt capital markets for life sciences clients; competes with EVOLUTION while serving a broader cross-sector franchise.

Direct peers

• Jefferies: Global investment bank with a large healthcare investment banking franchise covering biotech, pharma, and medical device M&A and capital raising; a primary competitor for mid- and large-cap healthcare mandates that EVOLUTION also targets.
• Canaccord Genuity: Global capital markets group with an active healthcare investment banking practice advising biotech and medtech on equity offerings and M&A; competes with EVOLUTION for mid-market healthcare mandates.
• Piper Sandler: Diversified investment bank with a dedicated healthcare group that advises biotech, medical device, and diagnostics companies on M&A, IPOs, and follow-on offerings, directly overlapping with EVOLUTION's core service lines.
• Leerink Partners: Healthcare-focused investment bank providing M&A, equity capital markets, and strategic advisory to life sciences companies; competes directly with EVOLUTION in biotech advisory mandates but operates at significantly larger scale.
• TD Cowen (Cowen and Company): Healthcare-focused investment bank (now part of TD) with strong biotech equity capital markets and M&A advisory franchise; a key competitor for the same biotech issuers EVOLUTION serves.
• H.C. Wainwright & Co. Healthcare-focused boutique investment bank with deep biotech capital markets and M&A capabilities; most direct comparable to EVOLUTION in size, sector focus, and client base.
• Oppenheimer & Co. Diversified investment bank with a healthcare group providing M&A advisory and capital raising services to life sciences clients; overlaps with EVOLUTION in serving emerging and mid-cap biotech.
• Raymond James: Diversified financial services firm with a healthcare investment banking practice covering biotech, medical device, and diagnostics M&A and capital markets; competes with EVOLUTION in mid-market healthcare advisory.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EVOLUTION Life Science Partners